Evidence map›Paper›PMID 41049248›Full record

ArticleACS applied nano materials2023

Hemin-Coated Nanoparticles as Drug Delivery Vehicles for Chemotherapeutic Agents in Cancer Therapy.

Kailin Feng, Eunsoo Yoo, Daphne Nie, Shadi Houshyar Azar, Zhiliang Cheng, Ahmad Amirshaghaghi, Andrew Tsourkas

Abstract read
In one paragraph

Article in ACS applied nano materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kailin FengDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA.
Eunsoo YooCollege of Engineering, North Carolina Agricultural and Technical State University, Greensboro, NC 27411, USA.
Daphne NieDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA.
Shadi Houshyar AzarDepartment of Chemistry and Biochemistry, Rowan University, Glassboro, NJ 08028, USA.
Zhiliang ChengDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA.
Ahmad AmirshaghaghiDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA.
Andrew TsourkasDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA.

Funding

Combined magnetophoresis and photodynamic therapy for the treatment of TNBCR01EB028858 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI TSOURKAS, ANDREW · 2021 to 2024
$1.8M
Image-guided surgery and sonodynamic therapy with stroma-targeted theranostic nanoclustersR01EB029238 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI TSOURKAS, ANDREW · 2020 to 2023
$1.4M
NIBIB NIH HHS R01 EB028858NIBIB NIH HHS R01 EB029238
6 · The paper itself

Abstract

Chemotherapy holds a prominent position in contemporary cancer treatment modalities; however, poor water solubility, rapid clearance, and unintended side effects remain significant challenges. To mitigate these issues, various nanoparticle-based delivery systems have been devised to improve the pharmacokinetic and pharmacodynamic profiles of chemotherapeutic drugs. While biocompatible, most of these drug delivery systems include materials that are foreign to the human body. Consequently, it is critical for these materials to be effectively removed from the body to prevent potential toxicity. In this study, we introduce a nanoparticle-based system that utilizes only hemin, which is naturally found in the body, as an amphiphilic coating agent to facilitate the solubilization of hydrophobic drugs. Camptothecin (CPT), Paclitaxel (PTX), and Sorafenib (SOR) were each formulated into stable hemin-coated nanoparticles (HeminNPs). We demonstrate that hemin-coated CPT nanoparticles exhibit an improved safety profile and therapeutic efficacy, compared with the administration of CPT alone, in a murine tumor model of triple-negative breast cancer. Consequently, utilizing HeminNPs demonstrates potential in reducing off-target toxicity and amplifying the therapeutic effectiveness of cancer treatments, which may ultimately contribute to improved treatment outcomes for cancer patients.

Indexed as

anti-cancer agentsbiocompatibilitycamptothecinchemotherapyhemin nanoparticles

Identifiers

PMID41049248
PMCPMC12494173

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.